|
TAOK1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.39640000065933E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.2835999999572E-06 |
| Normal-vs-Stage2 |
4.751300E-04 |
| Normal-vs-Stage3 |
3.1216000007106E-08 |
| Normal-vs-Stage4 |
4.22019999946066E-07 |
| Stage1-vs-Stage2 |
8.892600E-01 |
| Stage1-vs-Stage3 |
2.317200E-01 |
| Stage1-vs-Stage4 |
1.498440E-01 |
| Stage2-vs-Stage3 |
3.205000E-01 |
| Stage2-vs-Stage4 |
2.494600E-01 |
| Stage3-vs-Stage4 |
7.191000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.37120000021085E-07 |
| Normal-vs-AfricanAmerican |
1.500480E-02 |
| Normal-vs-Asian |
6.88510000013132E-07 |
| Caucasian-vs-AfricanAmerican |
4.067400E-01 |
| Caucasian-vs-Asian |
2.049400E-01 |
| AfricanAmerican-vs-Asian |
1.161000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.27190036280922E-10 |
| Normal-vs-Female |
1.08590000003073E-06 |
| Male-vs-Female |
1.342280E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.00830000000041E-05 |
| Normal-vs-Age(41-60Yrs) |
5.67550000329931E-08 |
| Normal-vs-Age(61-80Yrs) |
3.17649999970193E-07 |
| Normal-vs-Age(81-100Yrs) |
4.983400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.416200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.585200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.907800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.722800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.005800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.363800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.676300E-02 |
| Classical-VS-Follicular |
2.030200E-01 |
| Classical-VS-Other |
1.240080E-03 |
| Classical-VS-Normal |
1.85040000000303E-06 |
| Tall-VS-Follicular |
3.683800E-01 |
| Tall-VS-Other |
1.433390E-01 |
| Tall-VS-Normal |
4.21129999983449E-07 |
| Follicular-VS-Other |
7.265000E-03 |
| Follicular-VS-Normal |
1.05800000005374E-06 |
| Other-VS-Normal |
1.47449999987614E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.81369999521885E-08 |
| Normal-vs-N1 |
2.48819999999483E-05 |
| N0-vs-N1 |
9.128800E-01 |
|
|
